GlassScriptPhysician profile
Robert R Kimmel
NPI 1912155706
$13,017.33
in general payments reported to CMS, 2019-2025
45 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,452 · 2020: $2,120 · 2021: $2,505 · 2022: $1,851 · 2023: $1,672 · 2024: $859 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,074 · Education: $15.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,073.85 |
| Education | $15.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,470.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,165.69 | 2019-2025 | |
| Lilly USA, LLC | $1,134.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,067.06 | 2019-2025 | Jardiance |
| Antares Pharma, INC. | $1,016.52 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amgen INC. | $923.80 | 2019-2025 | Evenity, Prolia, Tepezza |
| Ibsa Pharma INC. | $877.26 | 2019-2025 | Tirosint, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $728.54 | 2019-2022 | |
| Dexcom, INC. | $495.00 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $471.01 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $406.20 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Medtronic Minimed, INC. | $388.60 | 2019-2020 | |
| Abbott Laboratories | $376.57 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $341.17 | 2021-2025 | |
| Abbvie INC. | $333.72 | 2019-2023 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $223.15 | 2019-2024 | Tymlos |
| Medtronic, INC. | $166.47 | 2021 | |
| Tandem Diabetes Care, INC. | $138.52 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $135.90 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $130.89 | 2019-2020 | |
| Lifescan, INC. | $105.34 | 2020-2023 | |
| Madrigal Pharmaceuticals | $86.78 | 2025 | Rezdiffra |
| Chiasma, INC. | $84.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $77.27 | 2021-2024 | Strensiq |
| Mannkind Corporation | $76.59 | 2021-2025 | |
| Ultragenyx Pharmaceutical INC. | $69.37 | 2021-2023 | |
| Recordati_rare_diseases_inc. | $68.16 | 2021-2025 | Isturisa, Signifor Lar |
| Acella Pharmaceuticals, LLC | $52.13 | 2025 | NP Thyroid 60 |
| Nevro Corp. | $48.87 | 2021-2023 | Senza |
| Novartis Pharmaceuticals Corporation | $47.66 | 2025 | |
| Alfasigma USA, INC. | $40.39 | 2021 | |
| Kyowa Kirin, INC. | $33.93 | 2023 | Crysvita |
| Boston Scientific Corporation | $30.03 | 2019 | |
| Sequel Med Tech, LLC | $23.22 | 2025 | Twiist |
| Amryt Pharma Holdings LTD | $20.90 | 2021 | |
| Roche Diabetes Care, INC. | $20.74 | 2021 | |
| Ascendis Pharma Endocrinology INC | $19.92 | 2023 | |
| Amarin Pharma, INC. | $19.39 | 2019 | |
| Ascensia Diabetes Care US INC. | $17.64 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $14.77 | 2025 | |
| Cequr Corporation | $14.75 | 2023 | Cequr Simplicity |
| Beta Bionics, INC. | $14.60 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Horizon Therapeutics Plc | $14.12 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.65 | 2019 | |
| Eusa Pharma (US) LLC | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kimmel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.